Related by context. Frequent words. (Click for all words.) 63 comorbid conditions 61 posttreatment 61 psychosocial functioning 60 HRQoL 60 ADAS cog 59 symptom severity 59 Depressive symptoms 59 multivariate analyzes 59 extrapyramidal symptoms 58 liver biopsies 58 affective disorders 58 receiving VELCADE 58 thromboprophylaxis 58 vasomotor symptoms 58 XIENCE V demonstrated 57 Postoperative 57 postsurgical 57 somatic symptoms 57 HRQOL 57 FOLFOX4 57 Montgomery Asberg Depression 57 clinically meaningful improvement 57 dyspareunia 57 corticosteroid injections 57 QTc prolongation 57 lipid lowering therapy 57 hypoglycemic events 57 virologic response 57 Psoriasis Area 57 Negative Syndrome 57 beta blocker therapy 57 univariate 57 biochemical recurrence 57 QoL 57 neuroleptics 56 elevated CRP 56 antibiotic prophylaxis 56 adenotonsillectomy 56 Secondary endpoints included 56 depressive symptoms 56 postoperative complications 56 carotid stenosis 56 CI -#.# 56 annualized relapse 56 lipid parameters 56 comorbidity 56 psychoeducation 56 virologic 56 LUTS 56 HbA1c levels 56 nonoperative 56 juvenile idiopathic arthritis 56 interpersonal psychotherapy 56 retrospective cohort study 56 concomitant medications 56 platelet reactivity 56 morbidity mortality 56 Secondary endpoints include 56 analgesic efficacy 55 metastatic lung cancer 55 Secondary endpoints 55 neurologic symptoms 55 heparin induced thrombocytopenia 55 prodromal 55 stable angina 55 virological failure 55 pharmacological interventions 55 carotid intima media 55 revascularization procedures 55 sustained virologic response 55 T2DM 55 FDG PET 55 nonsignificant 55 paclitaxel eluting stents 55 covariate 55 metabolic parameters 55 urinary symptoms 55 tirofiban 55 fragility fractures 55 rEEG 55 prospectively defined 55 corticosteroid therapy 55 nonrandomized 55 Observational studies 55 P = .# 55 radical cystectomy 55 achieved statistical significance 55 atherothrombosis 55 #mg/day [001] 55 comorbidities 55 dysthymia 55 PREZISTA r 55 logistic regression analysis 55 chemoradiotherapy 55 secondary efficacy endpoints 55 thromboembolic 55 % CI #.#-#.# [006] 54 % CI #.#-#.# [007] 54 efficacy endpoint 54 nonadherence 54 PANSS